$1.08 Billion is the total value of Sofinnova Investments, Inc.'s 150 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KRTX | Karuna Therapeutics, Inc. | $135,763,000 | -4.4% | 1,885,602 | 0.0% | 12.56% | +22.6% | |
| ASND | Ascendis Pharma A/Sadr | $124,983,000 | -19.1% | 1,109,874 | 0.0% | 11.56% | +3.9% | |
| NXTC | Nextcure, Inc | $99,046,000 | -34.2% | 2,671,856 | 0.0% | 9.16% | -15.5% | |
| NTRA | Natera | $92,583,000 | -11.4% | 3,100,560 | 0.0% | 8.56% | +13.7% | |
| PRNB | Principia Biopharma | $84,157,000 | +8.4% | 1,417,258 | 0.0% | 7.78% | +39.1% | |
| YMAB | Y-mAbs Therapeutics, Inc | $57,271,000 | -16.5% | 2,194,278 | 0.0% | 5.30% | +7.2% | |
| CHRS | Coherus BioSciences | $31,357,000 | -9.9% | 1,933,221 | 0.0% | 2.90% | +15.6% | |
| GRTX | Galera Therapeutics, Inc | $29,295,000 | -27.8% | 3,083,712 | 0.0% | 2.71% | -7.4% | |
| MRUS | Merus N.V. | $23,729,000 | -14.1% | 1,961,039 | 0.0% | 2.20% | +10.3% | |
| AMRN | Amarinadr | $20,833,000 | -81.3% | 5,208,305 | 0.0% | 1.93% | -76.1% | |
| KNSA | Kiniksa Pharmaceuticals, Ltd | $14,283,000 | +40.0% | 922,700 | 0.0% | 1.32% | +79.5% | |
| Nucana Biomed Ltdordinary shares | $13,992,000 | -4.4% | 2,400,000 | 0.0% | 1.29% | +22.7% | ||
| NCNA | Nucana Biomed Ltdadr | $13,215,000 | -4.4% | 2,266,666 | 0.0% | 1.22% | +22.6% | |
| OBSV | ObsEva SA | $11,447,000 | -36.9% | 4,749,623 | 0.0% | 1.06% | -19.0% | |
| CHMA | Chiasma | $5,950,000 | -26.4% | 1,630,221 | 0.0% | 0.55% | -5.7% | |
| ITRM | Iterum Therapeutics | $4,679,000 | -39.8% | 1,726,514 | 0.0% | 0.43% | -22.7% | |
| ETTX | Entasis Therapeutics Holdings Inc. | $3,119,000 | -46.8% | 1,180,178 | 0.0% | 0.29% | -31.7% | |
| OTIC | Otonomy Inc | $2,986,000 | -48.6% | 1,515,629 | 0.0% | 0.28% | -34.0% | |
| ACRS | Aclaris Therapeutics | $1,988,000 | -45.0% | 1,911,573 | 0.0% | 0.18% | -29.2% | |
| APLS | Apellis Pharmaceuticals, Inc | $1,328,000 | -12.5% | 49,580 | 0.0% | 0.12% | +12.8% | |
| SYBX | Synlogic Inc. | $989,000 | -33.3% | 574,972 | 0.0% | 0.09% | -15.0% | |
| PDSB | PDS Biotechnology Corporation | $104,000 | -72.5% | 142,635 | 0.0% | 0.01% | -63.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.